[[abstract]]The use of benchmark dose (BMD) calculations for dichotomous or continuous responses is well established in the risk assessment of cancer and noncancer endpoints. In some cases, responses to exposure are categorized in terms of ordinal severity effects such as none, mild, adverse, and severe. Such responses can be assessed using categorical regression (CATREG) analysis. However, while CATREG has been employed to compare the benchmark approach and the no-adverse-effect-level (NOAEL) approach in determining a reference dose, the utility of CATREG for risk assessment remains unclear. This study proposes a CATREG model to extend the BMD approach to ordered categorical responses by modeling severity levels as censored interval limits...
The median effect equation (Chou, 1976) is developed and presented as a biologically plausible model...
We used the benchmark dose (BMD) methodology de-vised by Crump (Fundam. Appl. Toxicol. 4, 854–871, 1...
International audiencePhase I dose-finding trials in oncology seek to find the maximum tolerated dos...
[[abstract]]The use of benchmark dose (BMD) calculations for dichotomous or continuous responses is ...
[[abstract]]The benchmark dose (BMD) approach for the exposure limit in the risk assessment of cance...
The benchmark dose (BMD) method has been recommended to replace the no-observed-adverse-effect-level...
A major component of quantitative risk assessment involves dose-response modeling. Therein, an appro...
Model averaging has been shown to be a useful method for incorporating model un-certainty in quantit...
In drug development clinical trials are designed to investigate whether a new treatment is safe and ...
In this thesis, dose-response modeling and procedures for benchmark dose (BMD) analysis in health r...
International audienceWe propose a pharmacokinetic-pharmacodynamic (PK/PD) model (with possibly diff...
Safety assessment for noncancer health effects generally has been based upon dividing a no observed ...
Model averaging has been shown to be a useful method for incorporating model uncertainty in quantita...
To reduce uncertainty due to model selection when a large number of potential candidate models is av...
All forms of life are being exposed to different levels of harmful chemicals that can cause various ...
The median effect equation (Chou, 1976) is developed and presented as a biologically plausible model...
We used the benchmark dose (BMD) methodology de-vised by Crump (Fundam. Appl. Toxicol. 4, 854–871, 1...
International audiencePhase I dose-finding trials in oncology seek to find the maximum tolerated dos...
[[abstract]]The use of benchmark dose (BMD) calculations for dichotomous or continuous responses is ...
[[abstract]]The benchmark dose (BMD) approach for the exposure limit in the risk assessment of cance...
The benchmark dose (BMD) method has been recommended to replace the no-observed-adverse-effect-level...
A major component of quantitative risk assessment involves dose-response modeling. Therein, an appro...
Model averaging has been shown to be a useful method for incorporating model un-certainty in quantit...
In drug development clinical trials are designed to investigate whether a new treatment is safe and ...
In this thesis, dose-response modeling and procedures for benchmark dose (BMD) analysis in health r...
International audienceWe propose a pharmacokinetic-pharmacodynamic (PK/PD) model (with possibly diff...
Safety assessment for noncancer health effects generally has been based upon dividing a no observed ...
Model averaging has been shown to be a useful method for incorporating model uncertainty in quantita...
To reduce uncertainty due to model selection when a large number of potential candidate models is av...
All forms of life are being exposed to different levels of harmful chemicals that can cause various ...
The median effect equation (Chou, 1976) is developed and presented as a biologically plausible model...
We used the benchmark dose (BMD) methodology de-vised by Crump (Fundam. Appl. Toxicol. 4, 854–871, 1...
International audiencePhase I dose-finding trials in oncology seek to find the maximum tolerated dos...